Compositions and methods for producing a composition
Kirk J. Leister, Fayetteville, NY (US); Eugene J. Schaefer, Westfield, NJ (US); Ronald Charles Bates, Irvine, CA (US); Elizabeth A. Bramhall, Groton, MA (US); David Michael Didio, Syracuse, NY (US); Robert Donaldson, Southborough, MA (US); Alan R. Flesher, Lawrenceville, NJ (US); Helen Gray Haggerty, Manlius, NY (US); David Henry Kirkley, East Syracuse, NY (US); John Malcolm Tabor, Syracuse, NY (US); Lee K. Tay, Princeton Junction, NJ (US); Pallaiah Thammana, Manlius, NY (US); Ajoy Velayudhan, Cary, NC (US); David Edward Smolin, Pennington, NJ (US); Reb J. Russell, Doylestown, PA (US); Thomas James Vanden Boom, Flemington, NJ (US); Dean Woodrow Brownell, Oswego, NY (US); Jeffrey Schrimsher, Hillsborough, NC (US); and Joyce Patricia Whitehead, Manlius, NY (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Nov. 25, 2020, as Appl. No. 17/105,358.
Application 17/105,358 is a division of application No. 16/042,977, filed on Jul. 23, 2018, granted, now 10,941,189.
Application 16/042,977 is a division of application No. 12/086,786, granted, now 10,508,144, issued on Dec. 17, 2019, previously published as PCT/US2006/049074, filed on Dec. 19, 2006.
Claims priority of provisional application 60/752,267, filed on Dec. 20, 2005.
Claims priority of provisional application 60/752,150, filed on Dec. 20, 2005.
Claims priority of provisional application 60/849,543, filed on Oct. 5, 2006.
Prior Publication US 2021/0246188 A1, Aug. 12, 2021
1. A composition comprising cytotoxic T lymphocyte antigen 4-Ig (CTLA4-Ig) molecules, wherein the CTLA4-Ig composition comprises an average molar ratio of N-acetyl neuraminic acid (NANA) to CTLA4-Ig molecules of from about 8 to about 12; and wherein the CTLA4-Ig molecules comprise the amino acid sequence set forth in SEQ ID NO: 10.